
Kevin Runion
70.1K posts

Kevin Runion
@KPRunion
The world as I see and live it. I strive to embrace the new and respect some of the old.


What golf opinion makes you feel like this?





-I’m not aware of a money manager, real estate or otherwise, who hasn’t lost money on many investments over a career. It’s the nature of investing to potentially lose all equity and to think otherwise is naive and silly. It’s also dumb and small to celebrate somebody else’s failings. -I don’t know Brandon but respect posting this publicly when who knows the firestorm behind the scenes. -To in the third paragraph say “and this on a deal where rents were 30% higher…” feels like the start of a massive excuse/shift of blame and feels gross, in light of losing so much money. “I executed really well, but the market was against me!” Punctuated with “good deal gone bad.” That’s wrong. -To then say “so anybody can learn…” feels like losing $15M of hard-earned investor capital and making it an influencer post, which is also very lame. The “anyone” in bold is almost the worst part. “I lost a lot of people’s money. Here are the top ten things I learned.”

NOW: Mamdani says his admin will transfer ownership from bad landlords to non-profits. “For buildings that have suffered chronic neglect, we will work to transfer ownership to responsible stewards. Stewards that include community land trusts, non-profits, or even the tenants themselves.”



Reading glasses might be done. The FDA just approved a once-daily eye drop called VIZZ that sharpens near vision in about 30 minutes and keeps it sharp for up to 10 hours. One drop. Each eye. Per day. That's it. The active ingredient is aceclidine, a compound first used back in 1975 to treat glaucoma. Scientists figured out it could be repurposed to gently shrink the pupil, creating a "pinhole effect" that pulls close-up text back into focus, the same trick your eye does when you squint. Unlike Vuity, the 2021 drop that came before it, VIZZ doesn't mess with your focusing muscles. So no blurry distance vision. No brow ache. No weird zoom effect. It was tested across more than 30,000 treatment days with no major complications. Cost is roughly $2 a day. This matters because presbyopia, the age-related slide that hits most people between 40 and 45, already affects more than 120 million Americans. By 2030, the World Health Organization expects around 2 billion people worldwide to have it. LENZ Therapeutics, the maker, started rolling out samples in October. The squint era is ending. Source: Ynetnews, FOX 26 Houston, Yahoo News

NOW: Mamdani says his admin will transfer ownership from bad landlords to non-profits. “For buildings that have suffered chronic neglect, we will work to transfer ownership to responsible stewards. Stewards that include community land trusts, non-profits, or even the tenants themselves.”









